ストックスクリーナーアプリを入手
32.76
1.68%
-0.56
プレマーケット:
32.50
-0.26
-0.79%
前日終値:
$33.32
開ける：
$33.1
24時間の取引高:
842.86K
Relative Volume:
0.82
時価総額：
$1.89B
収益：
-
当期純損益:
$-100.44M
株価収益率:
-14.76
EPS:
-2.22
ネットキャッシュフロー:
$-105.32M
1週間 パフォーマンス:
+14.35%
1か月 パフォーマンス:
+20.09%
6か月 パフォーマンス:
+20.93%
1年 パフォーマンス:
-20.37%
1日の値動き範囲:
$31.77
$33.37
1週間の範囲:
$28.22
$34.10
52週間の値動き範囲:
$13.22
$42.22
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
名前
Structure Therapeutics Inc Adr
セクター
電話
(628) 229-9277
住所
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
GPCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
32.76 | 1.92B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-02 | 開始されました | Citigroup | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-21 | 開始されました | JP Morgan | Overweight |
| 2024-04-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-07-27 | 開始されました | Piper Sandler | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | Guggenheim | Buy |
| 2023-02-28 | 開始されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Structure Therapeutics Inc Adr (GPCR) 最新ニュース
Pier Capital LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.2%Still a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics - TipRanks
11,000 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by Allianz Asset Management GmbH - MarketBeat
Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Allianz Asset Management GmbH Purchases New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - Defense World
Jazz Pharmaceuticals (NASDAQ: JAZZ) names Ted W. Love, M.D., to board Dec 1, 2025 - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - NewsBreak: Local News & Alerts
Critical Survey: Alkermes (NASDAQ:ALKS) and Structure Therapeutics (NASDAQ:GPCR) - Defense World
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Kura Oncology (KURA) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN) and ProQR (PRQR) - The Globe and Mail
Pacific Heights Asset Management LLC Acquires New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX) - The Globe and Mail
(PDF) Structural basis for chemotype diversity in small molecule GLP-1 receptor agonist drug discovery - researchgate.net
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Abbott Laboratories (ABT) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Aclaris Therapeutics (ACRS) - The Globe and Mail
Structure Therapeutics Inc. (GPCR): Investor Outlook With A 142% Potential Upside - DirectorsTalk Interviews
Analysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $68.67 - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) PT at $68.67 - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Structure Therapeutics' (GPCR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Signaturefd LLC - Defense World
Piper Sandler Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World
Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.3%Should You Sell? - MarketBeat
ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan PLC, Merck & Co. Inc., Pfizer - The Globe and Mail
ABSSSI Market to Reach New Heights in Growth by 2034, - openPR.com
Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% HigherTime to Buy? - MarketBeat
ETFs Investing in Structure Therapeutics, Inc. Sponsored ADR Stocks - TradingView
Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense - The Globe and Mail
Structure Therapeutics Inc. (GPCR) Stock Analysis: Unveiling a Potential 189% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Banque Pictet & Cie SA Sells 11,365 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - BioSpace
Layoff Tracker: Heidelberg Cuts 75% of Staff After Missed Royalty Payment - BioSpace
Structure Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com India
Interactive Brokers Group, Inc. $IBKR Shares Acquired by Swedbank AB - Defense World
Sumitomo Mitsui DS Asset Management Company Ltd Makes New Investment in Confluent, Inc. $CFLT - Defense World
Exchange Traded Concepts LLC Buys 1,054 Shares of TKO Group Holdings, Inc. $TKO - Defense World
IFM Investors Pty Ltd Has $3.42 Million Stock Position in Annaly Capital Management Inc $NLY - Defense World
MongoDB, Inc. $MDB Shares Acquired by IFM Investors Pty Ltd - Defense World
Wealth Enhancement Advisory Services LLC Grows Stock Holdings in VanEck Semiconductor ETF $SMH - Defense World
Voya Investment Management LLC Buys 1,696 Shares of PriceSmart, Inc. $PSMT - Defense World
Voya Investment Management LLC Lowers Stock Position in Dutch Bros Inc. $BROS - Defense World
Vanguard Total International Bond ETF $BNDX Shares Bought by Exchange Traded Concepts LLC - Defense World
IFM Investors Pty Ltd Boosts Position in Evergy Inc. $EVRG - Defense World
IFM Investors Pty Ltd Grows Holdings in Trimble Inc. $TRMB - Defense World
UnitedHealth Group Incorporated $UNH Shares Acquired by Exchange Traded Concepts LLC - Defense World
Structure Therapeutics Inc Adr (GPCR) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.35%
大文字化:
|
ボリューム (24 時間):